The University of Pittsburgh Cancer Institute (UPCI) is a multidisciplinary cancer research center, with programs in basic research, translational research and clinical investigations; cancer control and population sciences, early diagnosis and treatment, and behavioral medicine research. In addition to its central role in all cancer research at the University of Pittsburgh, it has full responsibility for cancer education and a recently significantly expanded network of clinical care. The UPCI is comprised of faculty members from the University of Pittsburgh, with some members also from the nearby Carnegie Mellon University, and it utilizes the clinical facilities of the University of Pittsburgh Medical Center (UPMC) and UPMC Cancer Centers. The UPCI has established programs in: molecular and cellular oncology, molecular therapeutics and drug discovery, immunology, molecular virology, lung and thoracic malignancies, prostate and urologic cancers, head and neck cancer, biological therapeutics, brain tumors; cancer epidemiology, prevention and control; and behavioral medicine and oncology. To assist its research efforts, the UPCI maintains shared facilities including: Biostatistics, Clinical Research Services, Immunologic Monitoring Laboratory, Cellular Products Laboratory, Flow Cytometry, Peptide Synthesis, Animal, Glassware, Oligonucleotide, Cell and Tissue Imaging, PET, MRI, Basic Genomics and Proteomics, Clinical Proteomics, Vector, Transgenic and Chimeric Mouse, Tissue and Research Pathology Services (TARPS), Clinical Pharmacology and Analytical, Cancer Informatics Services, Investigational Drug Service, and Micro-array and Analysis Shared Services(MASS). This application requests continued cancer center support grant (CCSG) funding for the University of Pittsburgh Cancer Institute's program for years 17-22.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-21
Application #
7494675
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-10
Project End
2010-07-31
Budget Start
2008-08-01
Budget End
2010-07-31
Support Year
21
Fiscal Year
2008
Total Cost
$5,021,590
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Steinman, Justin; Epperly, Michael; Hou, Wen et al. (2018) Improved Total-Body Irradiation Survival by Delivery of Two Radiation Mitigators that Target Distinct Cell Death Pathways. Radiat Res 189:68-83
Yockey, Laura J; Jurado, Kellie A; Arora, Nitin et al. (2018) Type I interferons instigate fetal demise after Zika virus infection. Sci Immunol 3:
Chen, Jingci; Nagle, Alison M; Wang, Yu-Fen et al. (2018) Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors. J Biol Chem 293:3700-3709
Qin, Ye; Vasilatos, Shauna N; Chen, Lin et al. (2018) Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene :
Diaz-Perez, Julio A; Killeen, Meaghan E; Yang, Yin et al. (2018) Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis. J Invest Dermatol 138:2595-2605
Evdokimova, Viktoria N; Gandhi, Manoj; Nikitski, Alyaksandr V et al. (2018) Nuclear myosin/actin-motored contact between homologous chromosomes is initiated by ATM kinase and homology-directed repair proteins at double-strand DNA breaks to suppress chromosome rearrangements. Oncotarget 9:13612-13622
Bissel, Stephanie J; Gurnsey, Kate; Jedema, Hank P et al. (2018) Aged Chinese-origin rhesus macaques infected with SIV develop marked viremia in absence of clinical disease, inflammation or cognitive impairment. Retrovirology 15:17
Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi et al. (2018) Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene 37:4599-4610
Ancevski Hunter, Katerina; Socinski, Mark A; Villaruz, Liza C (2018) PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22:1-10
Luu, Thehang; Kim, Kyu-Pyo; Blanchard, Suzette et al. (2018) Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer. Breast Cancer Res Treat 167:469-478

Showing the most recent 10 out of 1187 publications